Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Retained Earnings (2019 - 2025)

Nanobiotix has reported Retained Earnings over the past 7 years, most recently at -$438.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 31.48% year-over-year to -$438.7 million; the TTM value through Dec 2025 reached -$438.7 million, down 31.48%, while the annual FY2025 figure was -$438.7 million, 31.48% down from the prior year.
  • Retained Earnings for Q4 2025 was -$438.7 million at Nanobiotix, down from -$428.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $792589.3 in Q2 2024 and troughed at -$438.7 million in Q4 2025.
  • A 5-year average of -$173.2 million and a median of -$134.0 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: surged 100.32% in 2022 and later plummeted 54116.17% in 2025.
  • Year by year, Retained Earnings stood at -$209.9 million in 2021, then skyrocketed by 72.27% to -$58.2 million in 2022, then increased by 26.6% to -$42.7 million in 2023, then plummeted by 681.08% to -$333.6 million in 2024, then tumbled by 31.48% to -$438.7 million in 2025.
  • Business Quant data shows Retained Earnings for NBTX at -$438.7 million in Q4 2025, -$428.1 million in Q2 2025, and -$333.6 million in Q4 2024.